ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
DexCom, Inc. (DXCM) stock surged +1.80%, trading at $89.91 on NASDAQ, up from the previous close of $88.32. The stock opened at $87.68, fluctuating between $86.41 and $90.63 in the recent session.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Employees | 9500 |
Beta | 1.14 |
Sales or Revenue | $3.62B |
5Y Sales Change% | 2.209% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |
DexCom, Inc. (NASDAQ: DXCM) stock price is $89.91 in the last trading session. During the trading session, DXCM stock reached the peak price of $90.63 while $86.41 was the lowest point it dropped to. The percentage change in DXCM stock occurred in the recent session was 1.8% while the dollar amount for the price change in DXCM stock was $1.59.
The NASDAQ listed DXCM is part of Medical - Devices industry that operates in the broader Healthcare sector. DexCom, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Sadie M. Stern
Executive Vice President & Chief HR Officer
Mr. Steven R. Pacelli
Executive Vice President & MD of Dexcom Ventures
Mr. Jacob Steven Leach
Executive Vice President & Chief Operating Officer
Mr. Sean Christensen
Director of Corporation Affairs & Head of Investor Relations
Mr. Matthew Dolan
Executive Vice President of Strategy, Corporation Devel. & Dexcom Labs
Mr. Jereme M. Sylvain
Executive Vice President, Chief Financial Officer & Chief Accounting Officer
Mr. Paul R. Flynn
Executive Vice President of Global Revenue
Mr. Kevin Ronald Sayer
Executive Chairman, Chief Executive Officer & Pres
Mr. Andrew K. Balo
Executive Vice President of Global Medical Affairs, Access & Evidence
Mr. Girish Naganathan
Executive Vice President of R&D and Chief Technology Officer
Mr. Shelly Ramasamy Selvaraj
Senior Vice President & Chief Information Officer
Mr. Michael Jon Brown
Executive Vice President & Chief Legal Officer
DXCM's closing price is 44.23% higher than its 52-week low of $62.34 where as its distance from 52-week high of $142.00 is -36.68%.
Number of DXCM employees currently stands at 9,500.
Official Website of DXCM is: https://www.dexcom.com
DXCM could be contacted at phone 858 200 0200 and can also be accessed through its website. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, United States.
DXCM stock volume for the day was 3.05M shares. The average number of DXCM shares traded daily for last 3 months was 3.43M.
The market value of DXCM currently stands at $35.13B with its latest stock price at $89.91 and 390.77M of its shares outstanding.